Award recordCONTRACT

AMNEAL PHARMACEUTICALS OF NEW YORK, LLC

PIID VA797P17J0046· VA Staff Offices· NAC PHARMACEUTICALS 36P797· 6505 · DRUGS AND BIOLOGICALS· FY2017· $187,871 net obligations· UEI LVEBAQTPN615· NY

Description

DEOBLIGATE FUNDS ON 797D70046 FOR THE BULK PURCHASE OF IBUPROFEN FOR THE REPACKAGING PROGRAM.

Base award description: IBUPROFEN 400MG, 600MG, AND 800MG TABLETS

First action · last action
2017-03-06 · 2017-06-13
Transactions
2
First transaction's obligation
$188,076
Base + all options value (sum of deltas)
$187,871
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
Parent IDV
VA797P17A0001
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 2 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$188,076$0Base award · 2017-03-06 · this action $188,076 · running total $188,076Modification P00001 · 2017-06-13 · this action -$205 · running total $187,871
  • Base2017-03-06+$188,076= $188,076
  • Mod P000012017-06-13-$205= $187,871
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2017-03-06+$188,076$188,076IBUPROFEN 400MG, 600MG, AND 800MG TABLETS
Mod P00001· FUNDING ONLY ACTION2017-06-13−$205$187,871DEOBLIGATE FUNDS ON 797D70046 FOR THE BULK PURCHASE OF IBUPROFEN FOR THE REPACKAGING PROGRAM.

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI LVEBAQTPN615)

AwardOffice · PSC / listingNet obligationsFY
36E79726A0013NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2026
36C26026F0059260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$319,399FY2026
36C26025F0044260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$173,089FY2025
36C26024F0050260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$185,400FY2024
36E79724A0001NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2024
36F79722D0161NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS$0FY2022

Other recipients under 6505 from NAC PHARMACEUTICALS 36P797 (most recent first)

AwardRecipientOfficeNet obligationsFY
VA797P17J0052MYLAN PHARMACEUTICALS INCNAC PHARMACEUTICALS 36P797$6,169FY2017
VA797P17J0051MYLAN PHARMACEUTICALS INCNAC PHARMACEUTICALS 36P797$17,881FY2017
VA797P17J0050MYLAN PHARMACEUTICALS INCNAC PHARMACEUTICALS 36P797$72,904FY2017
VA797P17J0048KREMERS URBAN PHARMACEUTICALS INC.NAC PHARMACEUTICALS 36P797$1,225,936FY2017
VA797P17J0053EXELAN PHARMACEUTICALS INCNAC PHARMACEUTICALS 36P797$88,200FY2017

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA797P17J0046_3600_VA797P17A0001_3600 · retrieved 2026-09-26.